Introduction
============

Second primary cancer (SPC) is one of the major prognostic factors among cancer survivors and it is estimated to be the sixth most common form of malignancy in the world [@b1]. Besides this general sense of priority, there should be a special emphasis on SPC research for various reasons, including the possibility of reducing risk of SPC through control of the relevant environmental, behavioral, and genetic factors, once these have been identified [@b2],[@b3]. Study of SPC will be rewarding if the scope and the strategies are properly set [@b4]. SPCs can be grouped according to major identified etiologies, such as syndromic, treatment related, and shared exposure related [@b3]. Carcinogenesis of SPC is a complex process [@b2],[@b5], which may be caused by interactions between treatment for the first cancer, the genetic predisposition, as well as environmental and behavioral factors. Nielsen and colleagues found that heterogeneity in the risk of SPC was substantial across cancer types, pointing out the need to consider the pairs of first and second cancers rather than the overall risk [@b6]. Monitoring of the associations of particular first and SPCs in different populations may reveal novel carcinogenic pathways relevant to SPC, which may result in clinical practice improvement.

Many multicenter studies on SPCs have been conducted but the concordance in the occurrence of SPCs between various centers has rarely been reported. Obviously, the incidence of any primary cancers is related to the incidence of SPCs [@b7]. The present study is devoted to the comparison of the occurrence and ranking of specific SPC after 10 common first primaries between Germany and Sweden by using population-based cancer registries. Even though the overall cancer incidence is not very different between Sweden and the German cancer registries, rates of individual cancers differ, most notably for high rates in lung- and smoking-related cancers in German men, high prostate cancer rates in Swedish men, and somewhat higher colorectal cancer (CRC) rates among German men and women (Cancer Incidence in Five Continents IX, <http://www.iarc.fr>).

Patients and Methods
====================

The present study used the data from two sources. One is the Swedish Family-Cancer Database which includes data on 12.1 million individuals in the latest update of the year 2008, and over 1.1 million cancer patients, retrieved from the Swedish Cancer Registry (1958--2008) [@b8]. The other source is the pooled dataset from 11 German cancer registries including data on 1.1 million cancer patients diagnosed between 1997 and 2006, covering a population of 33 million people [@b9]. The present study included 10 of these Germany cancer registries. For comparisons, the present study thus included only the cancer patients diagnosed during 1997--2006 from the two datasets. An ad hoc study of the diagnostic accuracy of second cancers in the Swedish Cancer Registry indicated that 98% were correctly classified [@b10], and the German cancer registries strictly followed the multiple primary coding rules of the International Agency for Research on Cancer (IARC). In the Swedish Cancer Registry, the basic coding of tumor site has been performed according to ICD-O/2 (1993--2004) and ICD-O/3 (2005-w) and the different classifications are translated to ICD-7 to enable longer trends (codes: 140-197, 200-209). In the German dataset, tumors were identified based on ICD-O/3 and later converted into ICD-10 (codes: C00-C75, C81-C96). The case numbers of the 10 common first primary cancers for the German and Swedish datasets are shown in Table [1](#tbl1){ref-type="table"}. The SPCs were grouped into thirty major types in present study.

###### 

Case numbers of selected 10 first cancers in Germany and Sweden (1997--2006)

  First cancer sites   Germany   Sweden
  -------------------- --------- --------
  Colorectum           149,038   38,789
  Lung                 98,856    24,953
  Breast               149,471   51,691
  Endometrium          28,215    10,373
  Prostate             126,928   66,057
  Kidney               35,900    7545
  Urinary bladder      41,274    15,963
  Melanoma             33,194    14,703
  NHL                  29,034    11,592
  Leukemia             20,058    10,504

NHL, non-Hodgkin\'s lymphoma.

Spearman\'s rank correlation coefficients were used to test the strength of the relationship of the ranks of thirty possible SPCs after site-specific first primaries between the German and Swedish datasets. All the analyses were carried out by using SAS software version 9.2. The study was approved by the local ethics committees and the recommendations of Declaration of Helsinki had been followed.

Results
=======

Table [2](#tbl2){ref-type="table"} provides a summary of the five most common SPCs following 10 common first cancers in Germany and Sweden. The five leading SPCs after kidney cancer were identical between the two datasets, including prostate, colorectal, urinary bladder, lung, and breast cancers. For non-Hodgkin\'s lymphoma (NHL) and leukemia, the same order of the five SPCs was also observed in the two datasets. In addition, the three most common SPCs after prostate cancer, ranked in descending prevalence, were CRC (20.9% in Germany vs. 23.7% in Sweden), bladder cancer (20.0% vs. 17.8%), and lung cancer (14.3% vs. 12.3%) (Table [2](#tbl2){ref-type="table"}). For the remaining first cancers, four of the five leading SPCs were identical in the two populations (Table [2](#tbl2){ref-type="table"}). For instance, the four SPCs after CRC were prostate, lung, breast, and kidney cancers. For lung cancer, the SPCs were the tumors of prostate, colorectum, urinary bladder, and upper aerodigestive tract. For breast cancer, the SPCs were colorectal, endometrial, lung, and ovary cancers. Breast cancer, ovary cancer, CRC, and lung cancers were the four SPCs after endometrial cancer. Bladder cancer was followed by the four SPCs including prostate cancer, lung cancer, CRC, and kidney cancer. Prostate cancer (18.6% vs. 29.3%), breast cancer (14.4% vs. 15.6%), CRC (13.8% vs. 12.3%), and lung cancer (9.1% vs. 6.3%) following melanoma were found for the two datasets.

###### 

Occurrence of the five most common SPCs and rank correlations of SPCs after 10 common first cancers between Germany and Sweden (1997--2006)

  First cancers   Germany      Sweden   Germany vs. Sweden                                        
  --------------- ------------ -------- -------------------- ------------ ------ ------ --------- --
  Colorectum      Prostate     1050     20.1                 Prostate     584    27.2             
  Lung            596          11.4     Breast               247          11.5                    
  Breast          524          10.0     Lung                 187          8.7                     
  Kidney          444          8.5      Bladder              182          8.5                     
  Stomach         335          6.4      Kidney               98           4.6    0.90   \<0.001   
  Lung            Prostate     310      15.9                 Prostate     116    21.0             
  Colorectum      256          13.1     Colorectum           75           13.6                    
  UADT            249          12.8     Breast               61           11.1                    
  Bladder         163          8.4      Bladder              53           9.6                     
  Kidney          147          7.6      UADT                 28           5.1    0.86   \<0.001   
  Breast          Colorectum   674      19.8                 Colorectum   392    19.0             
  Endometrium     490          14.4     Endometrium          269          13.0                    
  Lung            296          8.7      Lung                 241          11.7                    
  Ovary           243          7.1      Ovary                130          6.3                     
  Kidney          235          6.9      Melanoma             129          6.2    0.85   \<0.001   
  Endometrium     Breast       391      27.7                 Breast       215    28.2             
  Ovary           288          20.4     Colorectum           137          18.0                    
  Colorectum      186          13.2     Ovary                106          13.9                    
  Lung            74           5.2      Lung                 41           5.4                     
  Kidney          62           4.4      Leukemia             28           3.7    0.83   \<0.001   
  Prostate        Colorectum   1188     20.9                 Colorectum   963    23.7             
  Bladder         1139         20.0     Bladder              724          17.8                    
  Lung            811          14.3     Lung                 500          12.3                    
  Kidney          570          10.0     Melanoma             240          5.9                     
  Stomach         337          5.9      NHL                  235          5.8    0.96   \<0.001   
  Kidney          Prostate     598      28.4                 Bladder      143    23.9             
  Colorectum      285          13.5     Prostate             143          23.9                    
  Bladder         278          13.2     Colorectum           56           9.3                     
  Lung            193          9.2      Lung                 52           8.7                     
  Breast          138          6.6      Breast               46           7.7    0.81   \<0.001   
  Bladder         Prostate     2037     55.1                 Prostate     844    45.4             
  Lung            446          12.1     Lung                 212          11.4                    
  Colorectum      318          8.6      Colorectum           174          9.4                     
  Kidney          258          7.0      Kidney               153          8.2                     
  Stomach         84           2.3      Breast               72           3.9    0.72   \<0.001   
  Melanoma        Prostate     224      18.6                 Prostate     272    29.3             
  Breast          174          14.4     Breast               145          15.6                    
  Colorectum      167          13.8     Colorectum           114          12.3                    
  Lung            110          9.1      Lung                 58           6.3                     
  Kidney          85           7.0      Bladder              45           4.8    0.85   \<0.001   
  NHL             Lung         166      14.8                 Prostate     138    20.3             
  Colorectum      152          13.6     Colorectum           90           13.3                    
  Prostate        148          13.2     Lung                 58           8.5                     
  Breast          96           8.6      Leukemia             55           8.1                     
  Leukemia        81           7.2      Breast               45           6.6    0.91   \<0.001   
  Leukemia        Prostate     112      16.1                 Prostate     111    19.5             
  Colorectum      99           14.2     Lung                 74           13.0                    
  Lung            98           14.1     Colorectum           72           12.7                    
  NHL             76           10.9     NHL                  42           7.4                     
  Breast          50           7.2      Breast               40           7.0    0.90   \<0.001   

SPCs, second primary cancers; UADT, upper aerodigestive tract; NHL, non-Hodgkin\'s lymphoma.

Spearman\'s correlation coefficient (*r*~s~) was calculated based on the ranks of 30 possible SPCs after first cancers.

Spearman\'s rank correlation coefficients showed that there was a strong positive correlation based on the ranks of thirty possible SPCs after all selected first cancers between the two datasets. Spearman\'s correlation coefficient (*r*~s~) was 0.90 for CRC, 0.86 for lung cancer, 0.85 for breast cancer, 0.83 for endometrial cancer, 0.96 for prostate cancer, 0.81 for kidney cancer, 0.72 for bladder cancer, 0.85 for melanoma, 0.91 for NHL, and 0.90 for leukemia. *P* values for all these *r*~s~ were less than 0.001 (Table [2](#tbl2){ref-type="table"}).

Figures [1](#fig01){ref-type="fig"}, [2](#fig02){ref-type="fig"} show percentage of all discordant SPCs combined following 10 common first cancers by sex in Germany and Sweden. The order of 10 common first cancers, ranked in descending incidence of the SPCs after the respective first cancers, was similar in the two populations, irrespective of the patients\' gender. For instance, male patients with bladder cancers had the highest incidence of the SPCs (11.5% vs. 13.0%), and those with lung cancers had the lowest incidence of the SPCs (2.3% vs. 2.3%) (Fig. [1](#fig01){ref-type="fig"}). For female patients, the highest SPC incidence appeared after endometrial cancers (5.0% vs. 7.4%) and the lowest one appeared after lung cancer (1.8% vs. 2.1%) in the two datasets (Fig. [2](#fig02){ref-type="fig"}).
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Discussion
==========

To our knowledge, this is the first comprehensive population-based comparison of SPCs in different populations. When comparing the ranking and proportion of the five most common SPCs after particular first primary cancers between the two populations, we found that there was a similar order of the five leading SPCs after most selected first primaries, especially for kidney cancer, NHL, and leukemia (Table [2](#tbl2){ref-type="table"}). Furthermore, high positive correlations between the German and Swedish datasets were observed based on the ranks of thirty possible SPCs after all selected first cancers (Table [2](#tbl2){ref-type="table"}). Of course the high correlation is driven by the overall incidence of cancers, including SPCs but nevertheless the consistent findings in the two populations provide support for the existence of uniform etiological processes underlying SPCs.

An important question in discussing similarities in the occurrence of SPCs is the incidence of first primary cancers. According to Cancer Incidence in Five Continents IX (<http://www.iarc.fr>), the male incidence of all cancers (around year 2000, without skin cancer) was 261 in Sweden (per 100,000) compared with 332 in Saarland, 345 in Mecklenburg-Western Pomerania, 315 in Munster, and 291 in Hamburg (as examples of the German rates, provided by these cancer registries). The differences were largely explained by tobacco-related sites because the incidence in lung cancer was almost three times higher in German men compared with Swedes. CRC was also more common in Germany while the opposite was true for prostate cancer; however, even for these cancers the Swedish rates were approximately within the incidence range in Germany. For women, the incidence of all cancer in Sweden was between the individual rates for the German cancer registries, and this applied to practically all individual sites.

Major strengths of this study are its design of population-based comparison and its subanalysis by specific SPCs. Analysis of large cancer registries including the Swedish Cancer Registry has consistently shown an excess burden of all SPCs combined, that is, there is an increased risk to develop any SPC after a primary cancer [@b11]--[@b17]. However, the present analysis by specific SPCs showed a more thorough picture, in which the more detailed information may reveal a compelling clinical agenda. However, it is important to keep in mind that surveillance bias may contribute to an excess risk of SPCs. Chance findings are also possible but the consistent results for the two datasets should reduce such possibilities.

In this study, the correlation coefficients for SPCs after 10 common cancers other than bladder cancer (*r*~s~: 0.72) were greater than 0.80, indicating strikingly consistent patterns for developing a specific SPC in the two populations. Additionally, the five most common SPCs after kidney cancer, NHL, or leukemia were totally identical between the two datasets, and those after CRC, lung cancer, breast cancer, endometrial cancer, bladder cancer, or melanoma was 80% identical (4/5). The present findings showed that prostate cancer was the most common SPC in male cancer survivors with CRC, kidney cancer, bladder cancer, melanoma, or leukemia in the two populations, and breast cancer was the most common one after endometrial cancer. Although the detection of these SPCs may often be affected by general population screening such as screening mammography and prostate-specific antigen screening, aggregate data on SPCs and the specific risk data may certainly guide surveillance protocols tailored to the SPCs in question and inform decisions about personalized medicine. Taken together, the above consistent findings in the two populations should facilitate early detection and treatment of SPC [@b18].

State-of-the-art investigations on SPCs should also cover genetic predisposition [@b19]. A recent genome-wide association study (GWAS) successfully explored the common genetic variations associated with susceptibility to SPCs [@b20]. This study was conducted in survivors of Hodgkin\'s lymphoma treated with radiotherapy, and successfully identified a set of single nucleotide polymorphisms (SNPs) at chromosome 6p21 that were strongly associated with SPC risk. Such studies may shed light on the way for further investigations of the complex interactions between genetic and environmental factors involved in the development of SPC [@b21]. Heterogeneity among the SPCs, however, was substantial, pointing out the need for separate evaluations by specific first and second primary pairs to explore the etiology of SPCs [@b22]. A 2007 study showed a common genetic risk factor (Chr. 8q24 variants) for colorectal and prostate cancers [@b23]. The present study supported the association between these two cancers at a population level and through replications in the two populations. The associations between first and SPCs may reflect emerging research priorities into SPC. For instance, there has been inconsistent evidence of excess bladder cancer after prostate cancer [@b24]--[@b27]. A number of studies linked an increased risk of bladder cancer specifically to prostate cancer radiotherapy or smoking [@b28]--[@b30].

In summary, the consistent patterns of the SPCs in the German and the Swedish populations were striking. Results on SPCs provide guidance to surveillance and early intervention strategies which should be tailored to specific SPCs. Effective prevention of SPCs requires a better understanding of their causes.
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